Eupraxia Pharmaceuticals Inc 2025年年度报告

(Exact name of registrant as specified in its charter) 201-2067 Cadboro Bay RoadVictoria, British Columbia, Canada V8R 5G4Telephone: (250) 590-3968 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (s.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit suchfiles).Yes☒No☐ If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has electednot to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section13(a) ofthe Exchange Act.☐ The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to itsAccounting Standards Codification after April5, 2012. Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internalcontrol over financial reporting under Section404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensationreceived by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Auditor Location:Vancouver, Canada Auditor Firm ID:85 PRINCIPAL DOCUMENTS The following documents are filed as part of this Annual Report on Form 40-F: A. Annual Information Form For the Registrant’s Annual Information Form for the year ended December31, 2025 (“AIF”), see Exhibit 99.1 of this Annual Report on Form40-F. B. Audited Annual Financial Statements For the Registrant’s Audited Consolidated Financial Statements as of and for the years ended December31, 2025 and 2024 (the “2025 FinancialStatements”), including the Report of the Independent Public Registered Accountant with respect thereto, see Exhibit 99.2 of this Annual Report onForm 40-F. C. Management’s Discussion and Analysis For the Registrant’s Management’s Discussion and Analysis of Financial Condition and Results of Operations for the year ended December31,2025 (“MD&A”), see Exhibit 99.3 of this Annual Report on Form 40-F. CONTROLS AND PROCEDURES A. Certifications The required disclosure is included in Exhibits 99.5, 99.6, 99.7 and 99.8 of this Annual Report on Form 40-F. B. Disclosure Controls and Procedures The information provided under the heading “Disclosure Controls and Procedures and Internal Controls Over Financial Reporting” contained inthe MD&A, filed as Exhibit 99.3 to this Annual Report on Form 40-F, is incorporated by reference herein. C. Management’s Annual Report on Internal Control over Financial Reporting and Attestation Report of the Registered Public Accounting Firm The information provided under the heading “Disclosure Controls and Procedures and Internal Controls Over Financial Reporting” contained inthe MD&A, filed as Exhibit 99.3 to this Annual Report on Form 40-F, is incorporated by reference herein. D. Changes in Internal Control over Financial Reporting The information provided under the heading “Disclosure Controls and Procedures and Internal Controls Over Financial Reporting” contained inthe MD&A, filed as Exhibit 99.3 to this Annual Report on Form 40-F, is incorporated by reference herein. NOTICES PURSUANT TO REGULATION BTR There were no notices required by Rule 104 of Regulation BTR that the Registrant sent during the year ended December31, 2024 concerning anyequity security subject to a blackout period under Rule 101 of Regulation BTR. AUDIT COMMITTEE FINANCIAL EXPERT The Registrant’s Board of Directors has determined that each member of the Audit Committee, John Montalbano, Simon Pimstone and PaulGeyer, are “independent” (as defined by Rule 10A-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Rule 5605(a)(2) ofThe Nasdaq Stock Market LLC (“Nasdaq”) Listing Rules) and that each of Mr.Montalbano and Dr.Pimstone are “audit committee financial experts”(as that term is defined in paragraph 8(b) of General Instruction B to Form 40-F). For a description of Mr.Montalbano’s and Dr.Pimstone’s relevant The Securities and Exchange Commission (“Commission”) has indicated that the designation or identification of a person as an audit committeefinancial expert does not make such person an “expert” for any purpose, impose any duties, obligations or liability on such person that are greater than CODE OF ETHICS The Board of Directors of the Registrant (the “Board”) has adopted a written code of business conduct and ethics (the “Code”) which emphasizesthe importance of matters relating to honest and ethical conduct, full, fair, accurate, timely, and understandable disclos